Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10

Multiple endocrine neoplasia type 2 is characterized by germline mutations in RET. For exon 10, comprehensive molecular and corresponding phenotypic data are scarce. The International RET Exon 10 Consortium, comprising 27 centers from 15 countries, analyzed patients with RET exon 10 mutations for clinical‐risk profiles. Presentation, age‐dependent penetrance, and stage at presentation of medullary thyroid carcinoma (MTC), pheochromocytoma, and hyperparathyroidism were studied. A total of 340 subjects from 103 families, age 4–86, were registered. There were 21 distinct single nucleotide germline mutations located in codons 609 (45 subjects), 611 (50), 618 (94), and 620 (151). MTC was present in 263 registrants, pheochromocytoma in 54, and hyperparathyroidism in 8 subjects. Of the patients with MTC, 53% were detected when asymptomatic, and among those with pheochromocytoma, 54%. Penetrance for MTC was 4% by age 10, 25% by 25, and 80% by 50. Codon‐associated penetrance by age 50 ranged from 60% (codon 611) to 86% (620). More advanced stage and increasing risk of metastases correlated with mutation in codon position (609→620) near the juxtamembrane domain. Our data provide rigorous bases for timing of premorbid diagnosis and personalized treatment/prophylactic procedure decisions depending on specific RET exon 10 codons affected. Hum Mutat 31:1–8, 2010. © 2010 Wiley‐Liss, Inc.

[1]  H. Gharib,et al.  Medullary thyroid cancer: management guidelines of the American Thyroid Association. , 2009, Thyroid : official journal of the American Thyroid Association.

[2]  A. Vortmeyer,et al.  Evidence of MEN-2 in the original description of classic pheochromocytoma. , 2007, The New England journal of medicine.

[3]  A. Pinchera,et al.  RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. , 2007, The Journal of clinical endocrinology and metabolism.

[4]  C. Eng,et al.  Clinical Predictors and Algorithm for the Genetic Diagnosis of Pheochromocytoma Patients , 2009, Clinical Cancer Research.

[5]  C. Deal,et al.  Prophylactic thyroidectomy in pediatric carriers of multiple endocrine neoplasia type 2A or familial medullary thyroid carcinoma: mutation in C620 is associated with Hirschsprung's disease. , 2007, Journal of pediatric surgery.

[6]  S. Borrego,et al.  The RET C620S mutation causes multiple endocrine neoplasia type 2A (MEN2A) but not Hirschsprung disease (HSCR) in a family cosegregating both phenotypes , 2003, Human mutation.

[7]  P. Bernante,et al.  Characterization of the largest kindred with MEN2A due to a Cys609Ser RET mutation , 2009, Familial Cancer.

[8]  M. Santoro,et al.  Molecular mechanisms of RET activation in human neoplasia , 1999, Journal of endocrinological investigation.

[9]  C. Eng,et al.  Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. , 2004, JAMA.

[10]  H. K. V. van Amstel,et al.  Familial medullary thyroid carcinoma: not a distinct entity? Genotype-phenotype correlation in a large family. , 1996, The American journal of medicine.

[11]  R. Weigel,et al.  When Is Prophylactic Thyroidectomy Indicated for Patients with the RET Codon 609 Mutation? , 2009, Annals of Surgical Oncology.

[12]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.

[13]  H. Buhr,et al.  Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype. , 2006, European journal of endocrinology.

[14]  S. Borrego,et al.  RET genotypes comprising specific haplotypes of polymorphic variants predispose to isolated Hirschsprung disease , 2000, Journal of medical genetics.

[15]  M. Schlumberger,et al.  Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients , 1998 .

[16]  M. Schlumberger,et al.  Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine. , 1998, Clinical endocrinology.

[17]  H. Siggelkow,et al.  Presentation of a kindred with familial medullary thyroid carcinoma and Cys611Phe mutation of the RET proto-oncogene demonstrating low grade malignancy. , 2001, European journal of endocrinology.

[18]  S. Hauptmann,et al.  Modification of multiple endocrine neoplasia 2A phenotype by cell membrane proximity of RET mutations in exon 10. , 2008, Endocrine-related cancer.

[19]  F. Nielsen,et al.  Is thyroidectomy necessary in RET mutations carriers of the familial medullary thyroid carcinoma syndrome? , 2000, Cancer.

[20]  J. Strauchen Germ-line mutations in nonsyndromic pheochromocytoma. , 2002, The New England journal of medicine.

[21]  M. Pembrey,et al.  Family screening in medullary thyroid carcinoma presenting without a family history. , 1988, The Quarterly journal of medicine.

[22]  John P. Bilezikian,et al.  CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2 , 2001 .

[23]  D. Easton,et al.  RISK ESTIMATION AND SCREENING IN FAMILIES OF PATIENTS WITH MEDULLARY THYROID CARCINOMA , 1988, The Lancet.

[24]  B. Kennedy,et al.  Cancer staging. , 1979, JAMA.

[25]  C. Eng,et al.  Age-related neoplastic risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germ line RET Cys634Trp (TGC>TGG) mutation. , 2008, Endocrine-related cancer.

[26]  S. Borrego,et al.  Specific polymorphisms in the RETproto-oncogene are over-represented in patients with Hirschsprung disease and may represent loci modifying phenotypic expression , 1999, Journal of medical genetics.

[27]  B. Ponder,et al.  Guidelines for diagnosis and therapy of MEN type 1 and type 2. , 2001, The Journal of clinical endocrinology and metabolism.

[28]  F. Wright,et al.  A founding locus within the RET proto-oncogene may account for a large proportion of apparently sporadic Hirschsprung disease and a subset of cases of sporadic medullary thyroid carcinoma. , 2003, American journal of human genetics.

[29]  R. DeLellis Pathology and genetics of tumours of endocrine organs , 2004 .

[30]  Charis Eng,et al.  Cancer phenomics: RET and PTEN as illustrative models , 2007, Nature Reviews Cancer.

[31]  C Eng,et al.  The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. , 1996, JAMA.

[32]  S. Borrego,et al.  Molecular analysis of the ret and GDNF genes in a family with multiple endocrine neoplasia type 2A and Hirschsprung disease. , 1998, The Journal of clinical endocrinology and metabolism.

[33]  C. Eng,et al.  Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. , 2005, JAMA.

[34]  S. Egawa,et al.  A nationwide clinical survey of patients with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma in Japan. , 1997, Japanese journal of clinical oncology.